Until now, the strongest evidence supporting ADCC as a key mechanism of some monoclonal antibodies was based on studies evaluating the impact of FcγRIIIa polymorphisms on clinical response to IgG1 mAbs such as rituximab in lymphoma patients (17, 18), trastuzumab in breast carcinomas (19) or cetuximab in colorectal carcinomas (6). This evidence concerns the gene FCGR3A and lymphoma.